Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
Twenty-seven patients with disseminated malignant melanoma were treated monthly with cisplatin (CDDP) 120 mg m-2 on day 1, vindesine (VDS) 3 mg m-2 on day 2 and dacarbazine (DTIC) 250 mg m-2 on days 2-6. None of them had received prior chemotherapy. All patients are evaluable for response and toxicity. There were five (19%) complete (CR) and seven (26%) partial (PR) responses for a total response rate of 45%. We conclude that the combination of DTIC, VDS and CDDP is capable of producing a relatively high rate of response in patients with advanced metastatic malignant melanoma, but responses are short.
Pectasides
D
D
Department of Medical Oncology, Metaxas Memorial Cancer Hospital, Piraeus, Greece.
Yianniotis
H
H
Alevizakos
N
N
Bafaloukos
D
D
Barbounis
V
V
Varthalitis
J
J
Dimitriadis
M
M
Athanassiou
A
A
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary*; D008875:Middle Aged; D012878:Skin Neoplasms / Q000188:drug therapy / Q000556:secondary; D014751:Vindesine / Q000008:administration & dosage
D003606:Dacarbazine; D002945:Cisplatin; D014751:Vindesine